Akèy › Karsinòm selil skuamèz tèt ak kou › Maryland › Baltimore
Etid klinik pou Karsinòm selil skuamèz tèt ak kou nan Baltimore, MD
15 etid pou Karsinòm selil skuamèz tèt ak kou ap chèche patisipan nan sit nan ak bò kote Baltimore (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ap rekriteFaz 2/3
- Site #0112, Baltimore
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #14, Baltimore
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Ap rekriteFaz 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Ap rekriteFaz 3
- University of Maryland Greenebaum Cancer Center, Baltimore
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Ap rekriteFaz 1/2
- University of Maryland School of Medicine, Baltimore
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 2
- University of Maryland/Greenebaum Cancer Center, Baltimore
- UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie · 9 mi lwen
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Ap rekriteFaz 2
- Greater Baltimore Medical Center, Baltimore
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- Research Site, Baltimore
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Ap rekriteEtid obsèvasyon
- University of Maryland, Baltimore
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Ap rekriteFaz 2
- Greater Baltimore Medical Center, Baltimore
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- Johns Hopkins Hospital /ID# 254056, Baltimore
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 3
- University of Maryland, Baltimore
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Ap rekriteFaz 2
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Baltimore Washington Medical Center, Glen Burnie · 9 mi lwen
- ak 1 plis
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Ap rekriteFaz 1/2
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Etid Karsinòm selil skuamèz tèt ak kou nan lòt vil
- Houston, TX47 etid
- Los Angeles, CA42 etid
- Boston, MA40 etid
- New York City, NY39 etid
- Nashville, TN39 etid
- St. Louis, MO28 etid
- Arlington, VA26 etid
- Philadelphia, PA26 etid
- Chicago, IL26 etid
- Atlanta, GA24 etid
- San Antonio, TX22 etid
- New Haven, CT22 etid
Lòt etid nan Baltimore
- Kansè Poumon ki pa ti selil60 etid
- Kansè nan tete47 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Kansè (tout kalite)37 etid
- Kansè pankreyas31 etid
- Kansè kolorektal31 etid
- Kansè Metastatik28 etid
- Obèsite26 etid
- Kansè vejik24 etid
- Ensifizyans kadyak24 etid
- Kansè ovè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.